{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T09:37:36Z","timestamp":1794649056330,"version":"4.9.1"},"reference-count":13,"publisher":"The Journal of Rheumatology","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Rheumatol"],"accepted":{"date-parts":[[2025,3,25]]},"published-print":{"date-parts":[[2025,9]]},"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>We aimed to compare the progression of systemic sclerosis\u2013associated interstitial lung disease (SSc-ILD) based on serological status.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      In a posthoc analysis of the SENSCIS trial (nintedanib vs placebo in SSc-ILD;\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/ClinicalTrials.gov\">ClinicalTrials.gov<\/jats:ext-link>\n                      :\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT02597933\">NCT02597933<\/jats:ext-link>\n                      ), we analyzed the rate of decline in forced vital capacity (FVC) over 52 weeks in 3 subsets: (1) positive for anticentromere antibody (ACA), (2) positive for anti-RNA polymerase III antibody (ARA), and (3) negative for ACA, ARA, and antitopoisomerase I antibody (ATA).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Among study participants who underwent baseline serological evaluation, 32\/549 (5.8%) were ACA positive, 98\/528 (18.6%) were ARA positive, and 127\/526 (24.1%) were negative for ACA, ARA, and ATA. Among the serological subsets of interest, in the placebo arm, the adjusted rate (standard error) of decline in FVC was \u221231.2 (41.5) mL\/year among participants who were positive for ACA and \u221264.7 (35.1) mL\/year among participants who were positive for ARA, numerically lower than in the overall SENSCIS trial population (\u221293.3 [13.5] mL\/yr). However, participants who were negative for ACA, ARA, and ATA experienced a numerically greater rate of decline in FVC than the overall trial population, both in those randomized to placebo (\u2212115.6 [35.4] mL\/yr vs \u221293.3 [13.5] mL\/yr) and those randomized to nintedanib (\u221291.8 [34.3] mL\/yr vs \u221252.4 [13.8] mL\/yr).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>These analyses of data from the SENSCIS trial suggest that patients with SSc-ILD who are ACA positive or ARA positive can experience progression of SSc-ILD. Patients negative for ACA, ARA, and ATA had a higher rate of progression than the overall trial population and should be monitored closely.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3899\/jrheum.2024-1063","type":"journal-article","created":{"date-parts":[[2025,4,15]],"date-time":"2025-04-15T08:46:01Z","timestamp":1744706761000},"page":"914-918","source":"Crossref","is-referenced-by-count":11,"title":["Outcomes in Systemic Sclerosis\u2013Associated Interstitial Lung Disease Based on Serological Profiles With a Focus on Anticentromere and Anti-RNA Polymerase III Antibodies"],"prefix":"10.3899","volume":"52","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3750-6569","authenticated-orcid":false,"given":"Elizabeth R.","family":"Volkmann","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8059-9978","authenticated-orcid":false,"given":"Shervin","family":"Assassi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3975-8938","authenticated-orcid":false,"given":"Christopher P.","family":"Denton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rozeta","family":"Simonovska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Sambevski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margarida","family":"Alves","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5560-6390","authenticated-orcid":false,"given":"Elana J.","family":"Bernstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2262","published-online":{"date-parts":[[2025,4,15]]},"reference":[{"key":"2025090105350876000_52.9.914.1","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1002\/art.41153","article-title":"Using autoantibodies and cutaneous subset to develop outcome-based disease classification in systemic sclerosis","volume":"72","author":"Nihtyanova","year":"2020","journal-title":"Arthritis Rheumatol"},{"key":"2025090105350876000_52.9.914.2","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1002\/art.38390","article-title":"Prediction of pulmonary complications and long-term survival in systemic sclerosis","volume":"66","author":"Nihtyanova","year":"2014","journal-title":"Arthritis Rheumatol"},{"key":"2025090105350876000_52.9.914.3","doi-asserted-by":"crossref","first-page":"1061738","DOI":"10.3389\/fmed.2022.1061738","article-title":"Comparing clinical characteristics of systemic sclerosis with or without interstitial lung disease: a cross-sectional study from a single center of the Chinese Rheumatism Data Center","volume":"9","author":"Li","year":"2022","journal-title":"Front Med"},{"key":"2025090105350876000_52.9.914.4","doi-asserted-by":"publisher","DOI":"10.1186\/ar3125"},{"key":"2025090105350876000_52.9.914.5","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1002\/acr2.11398","article-title":"The effect of anti-Scl-70 antibody determination method on its predictive significance for interstitial lung disease progression in systemic sclerosis","volume":"4","author":"Jandali","year":"2022","journal-title":"ACR Open Rheumatol"},{"key":"2025090105350876000_52.9.914.6","doi-asserted-by":"crossref","first-page":"2501","DOI":"10.1093\/rheumatology\/keac639","article-title":"Risk factors for lung function decline in systemic sclerosis-associated interstitial lung disease in a large single-center cohort","volume":"62","author":"Ramahi","year":"2023","journal-title":"Rheumatology"},{"key":"2025090105350876000_52.9.914.7","doi-asserted-by":"crossref","first-page":"rky002","DOI":"10.1093\/rap\/rky002","article-title":"Distinctive clinical phenotype of anti-centromere antibody-positive diffuse systemic sclerosis","volume":"2","author":"Caetano","year":"2018","journal-title":"Rheumatol Adv Pract"},{"key":"2025090105350876000_52.9.914.8","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1903076"},{"key":"2025090105350876000_52.9.914.9","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1002\/art.42861","article-title":"2023 American College of Rheumatology (ACR)\/American College of Chest Physicians (CHEST) guideline for the treatment of interstitial lung disease in people with systemic autoimmune rheumatic diseases","volume":"76","author":"Johnson","year":"2024","journal-title":"Arthritis Rheumatol"},{"key":"2025090105350876000_52.9.914.10","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.202306-1113ST"},{"key":"2025090105350876000_52.9.914.11","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1002\/art.41965","article-title":"Nintedanib in patients with systemic sclerosis-associated interstitial lung disease: subgroup analyses by autoantibody status and modified Rodnan skin thickness score","volume":"74","author":"Kuwana","year":"2022","journal-title":"Arthritis Rheumatol"},{"key":"2025090105350876000_52.9.914.12","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(16)30152-7"},{"key":"2025090105350876000_52.9.914.13","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1002\/acr2.11598","article-title":"Combining clinical and biological data to predict progressive pulmonary fibrosis in patients with systemic sclerosis despite immunomodulatory therapy","volume":"5","author":"Volkmann","year":"2023","journal-title":"ACR Open Rheumatol"}],"container-title":["The Journal of Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.3899\/jrheum.2024-1063","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T12:35:21Z","timestamp":1756730121000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.jrheum.org\/lookup\/doi\/10.3899\/jrheum.2024-1063"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,15]]},"references-count":13,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2025,9,1]]},"published-print":{"date-parts":[[2025,9]]}},"alternative-id":["10.3899\/jrheum.2024-1063"],"URL":"https:\/\/doi.org\/10.3899\/jrheum.2024-1063","relation":{},"ISSN":["0315-162X","1499-2752"],"issn-type":[{"value":"0315-162X","type":"print"},{"value":"1499-2752","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,15]]}}}